PURPOSE: Decision making in advanced cancer is increasingly complex. We developed a decision aid (DA) for patients with advanced colorectal cancer who are considering first-line chemotherapy and reviewing treatment options, prognostic information, and toxicities. We examined its impact on patient understanding, treatment decisions, decisional conflict, decision making, consultation satisfaction, anxiety, and quality of life by using a randomized trial design. PATIENTS AND METHODS: In all, 207 patients with colorectal cancer who were considering first-line chemotherapy for metastatic disease were randomly assigned to receive a standard medical oncology consultation or a consultation in which the DA (take-home booklet with audio recording, reviewed by an oncologist) was used. Participants completed questionnaires postconsultation, postdecision, and 1 month later. RESULTS: In this study, 100 patients were randomly assigned to the control arm, and 107 received the DA. Median age of the sample was 62 years, 58% were male, 89% had a performance status of 0 or 1, and 36% had received prior adjuvant chemotherapy. Patients receiving the DA demonstrated a greater increase in understanding of prognosis, options, and benefits, with higher overall understanding (P < .001). Decisional conflict, treatment decisions, and achievement of involvement preferences were similar between the groups. Anxiety was similar across groups and decreased over time. Most patients were confident in a decision during the first consultation; 74% chose chemotherapy, 7% supportive care alone, and 10% observation. CONCLUSION: This randomized trial of a decision aid in advanced cancer showed that its use in advanced colorectal cancer improved patient understanding of prognosis, treatment options, risks, and benefits without increasing anxiety. DAs can improve informed consent and can be tested through randomized trials even in the advanced cancer setting.
RCT Entities:
PURPOSE: Decision making in advanced cancer is increasingly complex. We developed a decision aid (DA) for patients with advanced colorectal cancer who are considering first-line chemotherapy and reviewing treatment options, prognostic information, and toxicities. We examined its impact on patient understanding, treatment decisions, decisional conflict, decision making, consultation satisfaction, anxiety, and quality of life by using a randomized trial design. PATIENTS AND METHODS: In all, 207 patients with colorectal cancer who were considering first-line chemotherapy for metastatic disease were randomly assigned to receive a standard medical oncology consultation or a consultation in which the DA (take-home booklet with audio recording, reviewed by an oncologist) was used. Participants completed questionnaires postconsultation, postdecision, and 1 month later. RESULTS: In this study, 100 patients were randomly assigned to the control arm, and 107 received the DA. Median age of the sample was 62 years, 58% were male, 89% had a performance status of 0 or 1, and 36% had received prior adjuvant chemotherapy. Patients receiving the DA demonstrated a greater increase in understanding of prognosis, options, and benefits, with higher overall understanding (P < .001). Decisional conflict, treatment decisions, and achievement of involvement preferences were similar between the groups. Anxiety was similar across groups and decreased over time. Most patients were confident in a decision during the first consultation; 74% chose chemotherapy, 7% supportive care alone, and 10% observation. CONCLUSION: This randomized trial of a decision aid in advanced cancer showed that its use in advanced colorectal cancer improved patient understanding of prognosis, treatment options, risks, and benefits without increasing anxiety. DAs can improve informed consent and can be tested through randomized trials even in the advanced cancer setting.
Authors: Allison J Applebaum; Elissa A Kolva; Julia R Kulikowski; Jordana D Jacobs; Antonio DeRosa; Wendy G Lichtenthal; Megan E Olden; Barry Rosenfeld; William Breitbart Journal: J Health Psychol Date: 2013-10-24
Authors: Inge Henselmans; Hanneke W M van Laarhoven; Pomme van Maarschalkerweerd; Hanneke C J M de Haes; Marcel G W Dijkgraaf; Dirkje W Sommeijer; Petronella B Ottevanger; Helle-Brit Fiebrich; Serge Dohmen; Geert-Jan Creemers; Filip Y F L de Vos; Ellen M A Smets Journal: Oncologist Date: 2019-11-26
Authors: Felicitas Hitz; Karin Ribi; Qiyu Li; Dirk Klingbiel; Thomas Cerny; Dieter Koeberle Journal: Support Care Cancer Date: 2013-07-05 Impact factor: 3.603
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: Alex Z Fu; Kristi D Graves; Roxanne E Jensen; John L Marshall; Margaret Formoso; Arnold L Potosky Journal: J Cancer Res Clin Oncol Date: 2015-11-18 Impact factor: 4.553
Authors: Michael R Gionfriddo; Aaron L Leppin; Juan P Brito; Annie Leblanc; Nilay D Shah; Victor M Montori Journal: J Comp Eff Res Date: 2013-11 Impact factor: 1.744